Leveraging AI to provides extensive coverage and actionable insights on global regulatory information for drugs, biologics, and devices of about 90 countries.
Online PR News – 05-April-2019 – Princeton, New Jersey – The growth in the number and complexity of regulations as well as quality standards will create challenges for companies to keep up. Traditional Regulatory intelligence (RI) systems are not keeping with changing times and adapting technology to get global Regulatory teams right Insights faster and cheaper. With a diversity of information sources, identifying and analyzing context based intelligence is challenging.
To address these, DDi brings VISTAAR.ai a Global Regulatory and Clinical Intelligence Platform which focuses exclusively on providing Regulatory Intelligence (RI) and Clinical Intelligence (Clin Intel) solution for drugs, devices, combination products, biologics, generics, active pharmaceutical ingredients and animal health drugs.
Vistaar combines regulatory content compiled by experts with advanced technology (AI) to deliver a unique intelligence solution addressing the regulatory landscape including Classification, Clinical, Marketing, Labeling, Safety, Variations, Imports/Exports and other key areas based on the inbuilt proprietary algorithms that align with regulatory and clinical business goals.